Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2008

View Archived Issues

Neurim Pharmaceuticals reports positive results with Neu-164 in experimental asthma and COPD

First-in-class protein kinase D inhibitor shows preclinical anticancer activity

New agents for metabolic disorders disclosed in recent patents

RNase L may be involved in the mode of action of lopinavir against HPV

Cellular assays with vorinostat in combination with conventional chemotherapy for SCLC

Recent Auspex patent reports novel anti-HIV agents

Recent patents impart new anticancer agents

Genentech reports progress of third quarter

FDA to review Targanta's NDA for oritavancin in cSSSI in November 2008

Epigenomics reports positive results from prognostic prostate cancer study

Tibotec enrolls patients in phase III telaprevir study in HCV

FDA approves Astepro for allergic rhinitis

Biothera initiates dosing in second arm of trial of Imprime PGG in mCRC

Pirfenidone approved in Japan for idiopathic pulmonary fibrosis

Exelixis submits diligence report to Bristol-Myers Squibb for Cdc7 inhibitor XL-413

AstraZeneca and Columbia University sign research collaboration in depression and anxiety

Cell Genesys terminates VITAL-1 trial of GVAX for prostate cancer and reports results from VITAL-2

WHO grants prequalified status to malaria drug Coarsucam

Jennerex completes treatment for first patient cohort in phase I clinical trial of JX-594

FDA approves Immutep's IND for phase I trial of ImmuFact in advanced pancreatic cancer

Alexza completes enrollment in second phase III AZ-004 trial

Australian TGA grants marketing approval to Abraxane in metastatic breast cancer

Celgene and Acceleron initiate phase II ACE-011 study

Daiichi Sankyo and Lilly respond to speculation about prasugrel NDA

Santen receives Japanese approval for Tapros in glaucoma and ocular hypertension

e-Therapeutics reports positive results from phase IIa clinical trial of ETX-9101 in asthma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026